Direct oral anticoagulants

Direct oral anticoagulants

Drug monograph · NCLEX study reference
Trade names	DOACs
Therapeutic class	Anticoagulant
Pharmacologic class	Direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitor (dabigatran)
Onset / peak / duration	Onset within hours; apixaban and dabigatran twice daily, rivaroxaban and edoxaban once daily.
Half-life / level	Half-life about 5 to 14 hours; no routine coagulation monitoring.
Routes	PO (oral)
High-alert (ISMP)	Yes
Black box warning	Yes (see Safety)
Antidote / reversal	Idarucizumab reverses dabigatran; andexanet alfa reverses factor Xa inhibitors; supportive care.
Pregnancy / lactation	Not recommended; use alternatives.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Direct oral anticoagulants (brand name DOACs) — Anticoagulant; Direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitor (dabigatran).

Identification

• Therapeutic class: Anticoagulant.
• Pharmacologic class: Direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitor (dabigatran).

Pharmacology

• Mechanism of action: Directly inhibit a single clotting factor (Xa or thrombin) to prevent clot formation; predictable effect without routine monitoring.
• Onset / peak / duration: Onset within hours; apixaban and dabigatran twice daily, rivaroxaban and edoxaban once daily.
• Half-life / therapeutic level: Half-life about 5 to 14 hours; no routine coagulation monitoring.

Clinical use

• Indications: Nonvalvular atrial fibrillation, venous thromboembolism treatment and prevention.
• Usual dose, route, frequency: PO once or twice daily by agent and indication.
• Maximum dose / adjustments: Adjust or avoid in renal impairment (dabigatran and edoxaban especially); rivaroxaban taken with food at higher doses.

Safety

• Contraindications: Active major bleeding, mechanical heart valves (use warfarin instead), severe renal impairment (agent specific).
• Black box warning: Premature discontinuation increases the risk of thrombotic events; spinal or epidural hematoma can occur with neuraxial anesthesia or spinal puncture (potential for paralysis).
• Interactions: Other anticoagulants and antiplatelets and NSAIDs (bleeding), strong CYP3A4 and P-gp inhibitors or inducers, St. John's wort (herbal).
• Pregnancy / lactation: Not recommended; use alternatives.
• High-alert: Yes.

Adverse effects

• Common side effects: Bruising, minor bleeding, GI upset (dabigatran dyspepsia).
• Serious effects to report: Major bleeding (GI, intracranial), spinal hematoma signs (back pain, leg weakness, numbness).
• Antidote / reversal: Idarucizumab reverses dabigatran; andexanet alfa reverses factor Xa inhibitors; supportive care.

Nursing process

• Assessment before administration: Bleeding risk, renal function, indication, neuraxial procedure timing.
• Interventions during therapy: Do not stop without provider guidance; hold appropriately around procedures; assess for bleeding.
• Monitor: Signs of bleeding, renal function, hemoglobin.
• Evaluation / expected outcome: Clot prevention without major bleeding.

Patient teaching

• Patient teaching: Do not skip or stop doses; report bleeding or unusual bruising; carry anticoagulant identification; do not crush dabigatran capsules and keep them in the original bottle.
• Notify provider if: Unusual bleeding or bruising, black stools, severe headache, back pain with leg weakness.
• Administration tips: Consistent timing; rivaroxaban higher doses with food; dabigatran kept in original packaging.